DAFTAR PUSTAKA
1. International Diabetes Federation. IDF Diabetes Atlas. Eighth. Karuranga S, Fernandes J da R, Huang Y, Malanda B, editors. United Kingdom:
Internation Diabetes Federation; 2017. 5–145 p.
2. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2015. PB PERKENI; 2015. 1–79 p.
3. Kasper D, Fauci A, Longo DL, Braunwald E. Harrrison’s Principles of Internal Medicine. 16th ed. New York: McGraw-Hill Medical; 2005. 1968–1993 p.
4. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli M V, et al. Global causes of blindness and distance vision impairment 1990 – 2020 : a systematic review and meta-analysis. Lancet Glob Heal.
2017;5(December):1221–34.
5. Sasongko MB, Widyaputri F, Agni AN. Prevalence of diabetic retinopathy and blindness in Indonesian adults with type 2 diabetes. Am J Ophthalmol [Internet]. Elsevier Inc.; 2018;181:79–87. Tersedia dari:
http://dx.doi.org/10.1016/j.ajo.2017.06.019
6. Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al.
Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care [Internet]. 2016 Sep 1;39(9):1643 LP – 1649. Tersedia dari:
http://care.diabetesjournals.org/content/39/9/1643.abstract
7. Vavvas DG, Thanos A, Patel A V, Miller JW. Basic Mechanisms of Pathologic Retinal and Choroidal Angiogenesis [Internet]. Sixth Edit. Vol. 1, Ryan’s Retina. Elsevier Inc.; 2019. 638–655 p. Tersedia dari:
http://dx.doi.org/10.1016/B978-0-323-40197-5.00028-1
8. Melancia D, Vicente A, Cunha JP, Abegao Pinto L, Ferreira J. Diabetic choroidopathy: a review of the current literature. Graefes Arch Clin Exp Ophthalmol. Germany; 2016 Aug;254(8):1453–61.
9. Lutty GA. Diabetic choroidopathy. Vision Res. England; 2017 Oct;139:161–7.
10. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol.
United States; 2009 May;147(5):811–5.
11. Hidayat AA, Fine BS. Diabetic choroidopathy. Light and electron microscopic observations of seven cases. Ophthalmology. United States;
1985 Apr;92(4):512–22.
12. Rosen RB, Hathaway M, Rogers J, Pedro J, Garcia P, Dobre GM, et al.
Simultaneous OCT/SLO/ICG imaging. Invest Ophthalmol Vis Sci. United States; 2009 Feb;50(2):851–60.
13. Wei X, Balne PK, Meissner KE, Barathi VA, Schmetterer L, Agrawal R.
Assessment of flow dynamics in retinal and choroidal microcirculation.
Surv Ophthalmol. United States; 2018 Sep;63(5):646–64.
14. Chhablani J, Wong IY, Kozak I. Choroidal imaging : A review. Saudi J
Ophthalmol [Internet]. Saudi Ophthalmological Society, King Saud
University; 2014;28(2):123–8. Tersedia dari:
http://dx.doi.org/10.1016/j.sjopt.2014.03.004
15. Regatieri C V., Branchini L, Fujimoto JG, Duker JS. Choroidal imaging using spectral-domain optical coherence tomography. Retina.
2012;32(5):865–76.
16. Kase S, Endo H, Takahashi M, Saito M, Yokoi M, Ito Y, et al. Alteration of choroidal vascular structure in diabetic retinopathy. Br J Ophthalmol.
England; 2019 Jun;
17. Abadia B, Sunen I, Calvo P, Bartol F, Verdes G, Ferreras A. Choroidal thickness measured using swept-source optical coherence tomography is reduced in patients with type 2 diabetes. PLoS One. United States;
2018;13(2):e0191977.
18. Gupta C, Tan R, Mishra C, Khandelwal N, Raman R, Kim R, et al.
Choroidal structural analysis in eyes with diabetic retinopathy and diabetic macular edema-A novel OCT based imaging biomarker. PLoS One. United States; 2018;13(12):e0207435.
19. Wang X-N, Li S-T, Li W, Hua Y-J, Wu Q. The thickness and volume of the choroid, outer retinal layers and retinal pigment epithelium layer changes in patients with diabetic retinopathy. Int J Ophthalmol. China;
2018;11(12):1957–62.
20. American Academy of Ophthalmology. Retina and Vitreous. In: American Academy of Ophthalmology, editor. Basic and Clinical Science Course.
San Francisco: American Academy of Ophthalmology; 2017.
21. Grant MB, Lutty GA. Retinal and Choroidal Vasculature: Retinal Oxygenation [Internet]. Sixth Edit. Vol. 1, Ryan’s Retina. Elsevier Inc.;
2019. 488–503 p. Tersedia dari: http://dx.doi.org/10.1016/B978-0-323- 40197-5.00020-7
22. American Academy of Ophthalmology. Retina and Vitreous. In: Basic and Clinical Science Course. San Francisco, CA: American Academy of Ophthalmology; 2015. p. 55–80.
23. Forrester J V. Anatomy of the eye and orbit. In: Forrester J V., editor. The Eye: Basic Sciences in Practice. Fourth Edi. Elsevier Inc.; 2016. p. 1- 102.e2.
24. Campos A, Campos EJ, Martins J, Ambrosio AF, Silva R. Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. Acta Ophthalmol. England; 2017 Aug;95(5):446–59.
25. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine, 18th Edition. 2011.
26. Wiley HE, Chew EY, Iii FLF. Nonproliferative Diabetic Retinopathy and Diabetic Macular Edema [Internet]. Sixth Edit. Vol. 47, Ryan’s Retina.
Elsevier Inc.; 2019. 1061–1090 p. Tersedia dari:
http://dx.doi.org/10.1016/B978-0-323-40197-5.00050-5
27. Skugor M. Diabetes Mellitus. In: Ryan’s Retina [Internet]. Sixth Edit.
Elsevier Inc.; 2019. p. 1055–60. Tersedia dari:
http://dx.doi.org/10.1016/B978-0-323-40197-5.00049-9
28. Hodgson NM, Zhu J, Wu F, Ferreyra HA, Zhang K. Diabetic Retinopathy:
Genetics and Etiologic Mechanisms. In: Ryan’s Retina [Internet]. Sixth Edit. Elsevier Inc.; 2019. p. 1038–54. Tersedia dari:
http://dx.doi.org/10.1016/B978-0-323-40197-5.00048-7
29. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI insight. United States; 2017 Jul;2(14).
30. Sun JK, Silva PS, Cavallerano JD, Blodi BA, Davis MD, Aiello LM, et al.
Proliferative Diabetic Retinopathy [Internet]. Sixth Edit. Vol. 1, Ryan’s Retina. Elsevier Inc.; 2019. 1091–1121 p. Tersedia dari:
http://dx.doi.org/10.1016/B978-0-323-40197-5.00051-7
31. Joussen AM, Stitt A, Lois N. Mechanisms of Macular Edema and Therapeutic Approaches [Internet]. Sixth Edit. Vol. 1, Ryan’s Retina.
Elsevier Inc.; 2019. 667-688.e5 p. Tersedia dari:
http://dx.doi.org/10.1016/B978-0-323-40197-5.00030-X
32. Chhablani J, Wong IY, Kozak I. Choroidal imaging: A review. Saudi J Ophthalmol Off J Saudi Ophthalmol Soc. 2014 Apr;28(2):123–8.
33. Yamashita T, Yamashita T, Shirasawa M, Arimura N, Terasaki H, Sakamoto T. Repeatability and reproducibility of subfoveal choroidal thickness in normal eyes of Japanese using different SD-OCT devices.
Invest Ophthalmol Vis Sci. United States; 2012 Mar;53(3):1102–7.
34. Branchini L, Regatieri C V, Flores-Moreno I, Baumann B, Fujimoto JG, Duker JS. Reproducibility of choroidal thickness measurements across three spectral domain optical coherence tomography systems.
Ophthalmology. United States; 2012 Jan;119(1):119–23.
35. Matsuo Y, Sakamoto T, Yamashita T, Tomita M, Shirasawa M, Terasaki H. Comparisons of choroidal thickness of normal eyes obtained by two different spectral-domain OCT instruments and one swept-source OCT instrument. Invest Ophthalmol Vis Sci. United States; 2013 Nov;54(12):7630–6.
36. Ding X, Li J, Zeng J, Ma W, Liu R, Li T, et al. Choroidal thickness in healthy Chinese subjects. Invest Ophthalmol Vis Sci. United States; 2011 Dec;52(13):9555–60.
37. Tan CS, Ouyang Y, Ruiz H, Sadda SR. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. United States; 2012 Jan;53(1):261–6.
38. Yilmaz I, Ozkaya A, Kocamaz M, Ahmet S, Ozkaya HM, Yasa D, et al.
Correlation Of Choroidal Thickness And Body Mass Index. Retina. United States; 2015 Oct;35(10):2085–90.
39. Sigler EJ, Randolph JC, Calzada JI, Charles S. Smoking and choroidal thickness in patients over 65 with early-atrophic age-related macular degeneration and normals. Eye (Lond). 2014 Jul;28(7):838–46.
40. Ulaş F, Doğan U, Duran B, Keleş A, Ağca S, Celebi S. Choroidal thickness changes during the menstrual cycle. Curr Eye Res. England; 2013
Nov;38(11):1172–81.
41. Wei W Bin, Xu L, Jonas JB, Shao L, Du KF, Wang S, et al. Subfoveal choroidal thickness: the Beijing Eye Study. Ophthalmology. United States;
2013 Jan;120(1):175–80.
42. Mohamed DMF, Hassan NA, Osman AA, Osman MH. Subfoveal choroidal thickness in diabetic macular edema. Clin Ophthalmol. 2019;13:921–5.
43. Kinoshita T, Imaizumi H, Shimizu M, Mori J, Hatanaka A, Aoki S, et al.
Systemic and Ocular Determinants of Choroidal Structures on Optical Coherence Tomography of Eyes with Diabetes and Diabetic Retinopathy.
Sci Rep. 2019 Nov;9(1):16228.
44. Xu J, Xu L, Du KF, Shao L, Chen CX, Zhou JQ, et al. Subfoveal choroidal thickness in diabetes and diabetic retinopathy. Ophthalmology. United States; 2013 Oct;120(10):2023–8.
45. Lee HK, Lim JW, Shin MC. Comparison of Choroidal Thickness in Patients with Diabetes by Spectral-domain Optical Coherence Tomography. Korean J Ophthalmol. 2013;27(6):433–9.
46. Langham ME, Grebe R, Hopkins S, Marcus S, Sebag M. Choroidal blood flow in diabetic retinopathy. Exp Eye Res. England; 1991 Feb;52(2):167–
73.
47. Unsal E, Eltutar K, Zirtiloğlu S, Dinçer N, Ozdoğan Erkul S, Güngel H.
Choroidal thickness in patients with diabetic retinopathy. Clin Ophthalmol [Internet]. Dove Medical Press; 2014 Mar 27;8:637–42. Tersedia dari:
https://pubmed.ncbi.nlm.nih.gov/24707168
48. Zhang Z, Meng X, Wu Z, Zou W, Zhang J, Zhu D, et al. Changes in Choroidal Thickness After Panretinal Photocoagulation for Diabetic Retinopathy: A 12-Week Longitudinal Study. Invest Ophthalmol Vis Sci [Internet]. 2015 Apr 29;56(4):2631–8. Tersedia dari:
https://doi.org/10.1167/iovs.14-16226
49. Regatieri C V, Branchini L, Carmody J, Fujimoto JG, Duker JS. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina. 2012 Mar;32(3):563–8.
50. Esmaeelpour M, Brunner S, Ansari-Shahrezaei S, Nemetz S, Povazay B, Kajic V, et al. Choroidal thinning in diabetes type 1 detected by 3- dimensional 1060 nm optical coherence tomography. Invest Ophthalmol Vis Sci. United States; 2012 Oct;53(11):6803–9.
51. Esmaeelpour M, Považay B, Hermann B, Hofer B, Kajic V, Hale SL, et al.
Mapping Choroidal and Retinal Thickness Variation in Type 2 Diabetes using Three-Dimensional 1060-nm Optical Coherence Tomography. Invest Ophthalmol Vis Sci [Internet]. 2011 Jul 15;52(8):5311–6. Tersedia dari:
https://doi.org/10.1167/iovs.10-6875
52. Sahinoglu-Keskek N, Altan-Yaycioglu R, Canan H, Coban-Karatas M.
Influence of glycosylated hemoglobin on the choroidal thickness. Int Ophthalmol. Netherlands; 2018 Oct;38(5):1863–9.
53. Bafiq R, Mathew R, Pearce E, Abdel-Hey A, Richardson M, Bailey T, et al. Age, Sex, and Ethnic Variations in Inner and Outer Retinal and Choroidal Thickness on Spectral-Domain Optical Coherence Tomography.
Am J Ophthalmol [Internet]. 2015 Nov;160(5):1034—1043.e1. Tersedia dari: https://doi.org/10.1016/j.ajo.2015.07.027
54. Ambiya V, Kumar A, Baranwal VK, Kapoor G, Arora A, Kalra N, et al.
Change in subfoveal choroidal thickness in diabetes and in various grades of diabetic retinopathy. Int J Retin Vitr. England; 2018;4:34.
55. Shen Z, Yang X, Xu J, She C, Wei W, Zhu W, et al. Association of choroidal thickness with early stages of diabetic retinopathy in type 2 diabetes. Int J Ophthalmol. 2017;10(4):613–8.
56. Shao L, Xu L, Chen CX, Yang LH, Du KF, Wang S, et al. Reproducibility of Subfoveal Choroidal Thickness Measurements with Enhanced Depth Imaging by Spectral-Domain Optical Coherence Tomography. Invest Ophthalmol Vis Sci [Internet]. 2013 Jan 9;54(1):230–3. Tersedia dari:
https://doi.org/10.1167/iovs.12-10351
57. Rahman W, Chen FK, Yeoh J, Patel P, Tufail A, Da Cruz L. Repeatability of Manual Subfoveal Choroidal Thickness Measurements in Healthy Subjects Using the Technique of Enhanced Depth Imaging Optical Coherence Tomography. Invest Ophthalmol Vis Sci [Internet]. 2011 Apr 8;52(5):2267–71. Tersedia dari: https://doi.org/10.1167/iovs.10-6024 58. Chhablani J, Barteselli G, Wang H, El-Emam S, Kozak I, Doede AL, et al.
Repeatability and Reproducibility of Manual Choroidal Volume Measurements Using Enhanced Depth Imaging Optical Coherence Tomography. Invest Ophthalmol Vis Sci [Internet]. 2012 Apr 24;53(4):2274–80. Tersedia dari: https://doi.org/10.1167/iovs.12-9435
Lampiran 1
Lampiran 2
Lampiran 3
Lampiran 4
KELOMPOK KONTROL NO INISIAL USIA
JENIS
KELAMIN HbA1C OD/OS TP TIO CT
1 UMU 46 L 5.5 OD 1.00 18 337
2 DDS 54 L 5.7 OD 1.00 17 252
3 DDS 54 L 5.7 OS 1.00 19 305
4 BLS 50 P 5.1 OD 1.00 12 227
5 BLS 50 P 5.1 OS 1.00 14 296
6 KUR 55 P 5.3 OD 1.00 13 219
7 KUR 55 P 5.3 OS 1.00 13 267
8 NNR 59 P 5.5 OD 1.00 19 299
9 NNR 59 P 5.5 OS 1.00 20 254
10 DNW 48 P 5.3 OD 1.00 9 178
11 DNW 48 P 5.3 OS 1.00 8 148
12 ICH 41 P 5.4 OD 1.00 17 368
13 ICH 41 P 5.4 OS 1.00 15 409
14 DDY 56 P 5.9 OD 1.00 16 273
15 DDY 56 P 5.9 OS 1.00 14 300
16 IIR 55 P 5.1 OD 1.00 13 404
17 IIR 55 P 5.1 OS 1.00 13 405
18 WWS 55 L 5.1 OS 0.63 17 150
19 INE 48 P 5.2 OD 1.00 17 255
20 INE 48 P 5.2 OS 1.00 17 342
21 TTS 47 P 5.3 OD 1.00 16 198
22 TTS 47 P 5.3 OS 1.00 20 165
23 PPM 51 P 5.4 OD 1.00 15 281
24 PPM 51 P 5.4 OS 1.00 15 289
25 TTR 54 P 5.6 OD 0.80 14 250
KELOMPOK DM TANPA RETINOPATI DIABETIK NO INISIAL USIA
JENIS KELAMIN
DURASI
DM HbA1C OD/OS TP IOP CT
1 AIN 55 P 8 8.8 OD 1.00 16 240
2 AIN 55 P 8 8.8 OD 1.00 21 295
3 AMH 54 L 10 8.6 OD 1.00 14 306
4 AMH 54 L 10 8.6 OS 1.00 15 292
5 ILA 57 P 7 11.8 OD 1.00 19 336
6 ILA 57 P 7 11.8 OS 1.00 19 351
7 EUS 46 P 3 9.7 OD 1.00 19 195
8 EUS 46 P 3 9.7 OS 1.00 18 255
9 IMS 43 P 0.3 7.7 OD 1.00 15 321
10 IMS 43 P 0.3 7.7 OS 1.00 14 295
11 IIT 53 P 0.0 8.8 OD 1.00 13 280
12 DDR 48 P 4 10 OD 1.00 16 276
13 DDR 48 P 4 10 OS 1.00 12 299
14 LLH 50 P 0 12.4 OD 1.00 18 295
15 LLH 50 P 0 12.4 OS 0.8 17 253
16 EUK 55 P 3 7.3 OD 0.8 15 299
17 EUK 55 P 3 7.3 OS 0.8 14 310
18 GUD 52 L 3 12.7 OD 1.00 15 164
19 IML 54 P 5 10.4 OD 1.00 15 269
20 IML 54 P 5 10.4 OS 1.00 14 174
21 RAT 48 P 5 11.2 OD 1.00 20 320
22 RAT 48 P 5 11.2 OS 1.00 18 261
23 ASW 49 L 1 7.7 OD 1.00 16 240
24 EUY 57 P 0 6.2 OD 1.00 13 277
25 EUY 57 P 0 6.2 OS 1.00 14 309
KELOMPOK DM DENGAN RETINOPATI DIABETIK NO INISIAL USIA JK DURASI
DM HbA1C OD/OS TP IOP SDR CT
1 HIS 44 P 3 7.5 OD 0.80 20 1 234
2 HIS 44 P 3 7.5 OS 0.63 20 2 343
3 IKA 56 P 13 7.8 OD 0.50 14 2 256
4 IKA 56 P 13 7.8 OS 0.80 16 2 228
5 EUW 55 P 15 8.6 OD 0.63 14 2 209
6 NAY 47 P 10 11.5 OS 1.00 12 2 280
7 WAM 48 P 14 7.6 0S 0.20 19 1 335
8 SOK 53 L 16 9.8 OS 0.63 15 2 244
9 KAR 53 P 5 9.9 OS 0.80 20 4 196
10 SNI 60 P 20 9.5 OS 0.32 15 3 206
11 SUM 49 P 15 12 OS 0.80 12 4 237
12 LNU 59 P 6 9.9 OS 0.40 12 2 242
13 OHO 51 P 2 5.5 OD 0.50 14 4 259
14 OHO 51 P 2 5.5 OS 0.80 14 4 237
15 NSU 49 P 4 11.3 OD 0.50 11 3 429
16 NSU 49 P 4 11.3 OS 0.20 12 1 307
17 RZT 50 P 5 10.8 OS 0.63 20 1 222
18 NNS 52 P 8 9.6 OD 0.20 20 1 240
19 UNT 54 L 16 9 OD 0.20 18 4 249
20 ESY 52 P 15 6.4 OD 0.40 15 4 288
21 ADM 49 P 15 8.5 OD 0.63 13 2 170
22 ADM 49 P 15 8.5 OS 0.50 13 3 122
23 PPN 55 L 2 12.6 OD 0.40 18 4 247
24 ASS 49 L 1 7.7 OS 0.40 12 4 240
25 IIT 53 P 0 8.8 OS 1.00 15 1 269
Lampiran 5
Lampiran 6
Explore
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Usia 48 100.0% 0 0.0% 48 100.0%
HbA1C 48 100.0% 0 0.0% 48 100.0%
PVA 48 100.0% 0 0.0% 48 100.0%
IOP 48 100.0% 0 0.0% 48 100.0%
CT 48 100.0% 0 0.0% 48 100.0%
Descriptives
Statistic Std. Error
Usia
Mean 51.6250 .61427
95% Confidence Interval for Mean
Lower Bound 50.3892 Upper Bound 52.8608
5% Trimmed Mean 51.7083
Median 52.0000
Variance 18.112
Std. Deviation 4.25578
Minimum 41.00
Maximum 60.00
Range 19.00
Interquartile Range 6.75
Skewness -.278 .343
Kurtosis -.252 .674
HbA1C
Mean 8.1875 .34855
95% Confidence Interval for Mean
Lower Bound 7.4863 Upper Bound 8.8887
5% Trimmed Mean 8.1134
Median 8.1500
Variance 5.831
Std. Deviation 2.41481
Minimum 5.10
Maximum 12.70
Range 7.60
Interquartile Range 4.38
Skewness .251 .343
Kurtosis -1.153 .674
PVA
Mean .7952 .03907
95% Confidence Interval for Mean
Lower Bound .7166
Upper Bound .8738
5% Trimmed Mean .8169
Median 1.0000
Variance .073
Std. Deviation .27069
Minimum .20
Maximum 1.00
Range .80
Interquartile Range .37
Skewness -.957 .343
Kurtosis -.504 .674
IOP
Mean 15.5417 .39608
95% Confidence Interval for Mean
Lower Bound 14.7449 Upper Bound 16.3385
5% Trimmed Mean 15.5833
Median 15.0000
Variance 7.530
Std. Deviation 2.74411
Minimum 9.00
Maximum 20.00
Range 11.00
Interquartile Range 4.75
Skewness -.018 .343
Kurtosis -.646 .674
CT
Mean 261.6875 8.33359
95% Confidence Interval for Mean
Lower Bound 244.9225 Upper Bound 278.4525
5% Trimmed Mean 259.2315
Median 253.5000
Variance 3333.539
Std. Deviation 57.73680
Minimum 150.00
Maximum 429.00
Range 279.00
Interquartile Range 64.50
Skewness .641 .343
Kurtosis .921 .674
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Usia .107 48 .200* .978 48 .487
HbA1C .141 48 .018 .920 48 .003
PVA .338 48 .000 .752 48 .000
IOP .120 48 .082 .962 48 .116
CT .098 48 .200* .968 48 .215
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Explore
[DataSet5] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik Durasi DM_Rev 4.sav
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Durasi DM 34 100.0% 0 0.0% 34 100.0%
Descriptives
Statistic Std. Error
Durasi DM
Mean 6.8912 1.01393
95% Confidence Interval for Mean
Lower Bound 4.8283 Upper Bound 8.9540
5% Trimmed Mean 6.6373
Median 5.0000
Variance 34.954
Std. Deviation 5.91220
Minimum .00
Maximum 20.00
Range 20.00
Interquartile Range 11.25
Skewness .623 .403
Kurtosis -.904 .788
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Durasi DM .184 34 .005 .894 34 .003
a. Lilliefors Significance Correction
Crosstabs
[DataSet4] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik _Rev 4.sav
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Kategori Usia * Kelompok 48 100.0% 0 0.0% 48 100.0%
Jenis kelamin * Kelompok 48 100.0% 0 0.0% 48 100.0%
Kategori Usia * Kelompok
Crosstab
Kelompok Total
Kontrol NDR DR
Kategori Usia
40-45 tahun
Count 1 1 1 3
Expected Count .9 .9 1.3 3.0
% within Kelompok 7.1% 7.1% 5.0% 6.3%
46-50 tahun
Count 5 5 7 17
Expected Count 5.0 5.0 7.1 17.0
% within Kelompok 35.7% 35.7% 35.0% 35.4%
51-55 tahun
Count 6 6 9 21
Expected Count 6.1 6.1 8.8 21.0
% within Kelompok 42.9% 42.9% 45.0% 43.8%
56-50 tahun
Count 2 2 3 7
Expected Count 2.0 2.0 2.9 7.0
% within Kelompok 14.3% 14.3% 15.0% 14.6%
Total
Count 14 14 20 48
Expected Count 14.0 14.0 20.0 48.0
% within Kelompok 100.0% 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig. (2- sided)
Pearson Chi-Square .104a 6 1.000
Likelihood Ratio .106 6 1.000
Linear-by-Linear Association .046 1 .830
N of Valid Cases 48
a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .88.
Jenis kelamin * Kelompok
Crosstab
Kelompok Total
Kontrol NDR DR
Jenis kelamin
Laki-laki
Count 3 3 4 10
Expected Count 2.9 2.9 4.2 10.0
% within Kelompok 21.4% 21.4% 20.0% 20.8%
Perempuan
Count 11 11 16 38
Expected Count 11.1 11.1 15.8 38.0
% within Kelompok 78.6% 78.6% 80.0% 79.2%
Total
Count 14 14 20 48
Expected Count 14.0 14.0 20.0 48.0
% within Kelompok 100.0% 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig. (2- sided)
Pearson Chi-Square .014a 2 .993
Likelihood Ratio .014 2 .993
Linear-by-Linear Association .011 1 .916
N of Valid Cases 48
a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is 2.92.
Explore
[DataSet4] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik _Rev 4.sav
Kelompok
Case Processing Summary
Kelompok Cases
Valid Missing Total
N Percent N Percent N Percent
Usia
Kontrol 14 100.0% 0 0.0% 14 100.0%
NDR 14 100.0% 0 0.0% 14 100.0%
DR 20 100.0% 0 0.0% 20 100.0%
HbA1C
Kontrol 14 100.0% 0 0.0% 14 100.0%
NDR 14 100.0% 0 0.0% 14 100.0%
DR 20 100.0% 0 0.0% 20 100.0%
PVA
Kontrol 14 100.0% 0 0.0% 14 100.0%
NDR 14 100.0% 0 0.0% 14 100.0%
DR 20 100.0% 0 0.0% 20 100.0%
IOP
Kontrol 14 100.0% 0 0.0% 14 100.0%
NDR 14 100.0% 0 0.0% 14 100.0%
DR 20 100.0% 0 0.0% 20 100.0%
Descriptives
Kelompok Statistic Std. Error
Usia Kontrol
Mean 51.3571 1.31185
95% Confidence Interval for Mean
Lower Bound 48.5231 Upper Bound 54.1912
5% Trimmed Mean 51.5079
Median 52.5000
Variance 24.093
Std. Deviation 4.90850
Minimum 41.00
Maximum 59.00
Range 18.00
Interquartile Range 7.25
Skewness -.529 .597
Kurtosis -.162 1.154
NDR
Mean 51.5000 1.13752
95% Confidence Interval for Mean
Lower Bound 49.0425 Upper Bound 53.9575
5% Trimmed Mean 51.6667
Median 52.5000
Variance 18.115
Std. Deviation 4.25622
Minimum 43.00
Maximum 57.00
Range 14.00
Interquartile Range 7.00
Skewness -.503 .597
Kurtosis -.599 1.154
DR
Mean 51.9000 .88823
95% Confidence Interval for Mean
Lower Bound 50.0409 Upper Bound 53.7591
5% Trimmed Mean 51.8889
Median 52.0000
Variance 15.779
Std. Deviation 3.97227
Minimum 44.00
Maximum 60.00
Range 16.00
Interquartile Range 5.75
Skewness .239 .512
Kurtosis .040 .992
HbA1C Kontrol
Mean 5.3857 .06364
95% Confidence Interval for Mean
Lower Bound 5.2482 Upper Bound 5.5232
5% Trimmed Mean 5.3730
Median 5.3500
Variance .057
Std. Deviation .23812
Minimum 5.10
Maximum 5.90
Range .80
Interquartile Range .35
Skewness .675 .597
Kurtosis .099 1.154
NDR
Mean 9.5214 .53413
95% Confidence Interval for Mean
Lower Bound 8.3675 Upper Bound 10.6753
5% Trimmed Mean 9.5294
Median 9.2500
Variance 3.994
Std. Deviation 1.99853
Minimum 6.20
Maximum 12.70
Range 6.50
Interquartile Range 3.65
Skewness .136 .597
Kurtosis -.960 1.154
DR
Mean 9.2150 .41513
95% Confidence Interval for Mean
Lower Bound 8.3461 Upper Bound 10.0839
5% Trimmed Mean 9.2333
Median 9.2500
Variance 3.447
Std. Deviation 1.85650
Minimum 5.50
Maximum 12.60
Range 7.10
Interquartile Range 2.85
Skewness -.032 .512
Kurtosis -.359 .992
PVA Kontrol
Mean .9593 .02906
95% Confidence Interval for Mean
Lower Bound .8965 Upper Bound 1.0221
5% Trimmed Mean .9753
Median 1.0000
Variance .012
Std. Deviation .10873
Minimum .63
Maximum 1.00
Range .37
Interquartile Range .00
Skewness -2.718 .597
Kurtosis 7.045 1.154
NDR
Mean .9857 .01429
95% Confidence Interval for Mean
Lower Bound .9549 Upper Bound 1.0166
5% Trimmed Mean .9952
Median 1.0000
Variance .003
Std. Deviation .05345
Minimum .80
Maximum 1.00
Range .20
Interquartile Range .00
Skewness -3.742 .597
Kurtosis 14.000 1.154
DR
Mean .5470 .05467
95% Confidence Interval for Mean
Lower Bound .4326 Upper Bound .6614
5% Trimmed Mean .5411
Median .5000
Variance .060
Std. Deviation .24450
Minimum .20
Maximum 1.00
Range .80
Interquartile Range .36
Skewness .347 .512
Kurtosis -.613 .992
IOP Kontrol
Mean 15.2143 .72762
95% Confidence Interval for Mean
Lower Bound 13.6424 Upper Bound 16.7862
5% Trimmed Mean 15.3492
Median 16.0000
Variance 7.412
Std. Deviation 2.72251
Minimum 9.00
Maximum 19.00
Range 10.00
Interquartile Range 4.00
Skewness -.876 .597
Kurtosis .515 1.154
NDR
Mean 16.0000 .59300
95% Confidence Interval for Mean
Lower Bound 14.7189 Upper Bound 17.2811
5% Trimmed Mean 15.9444
Median 15.5000
Variance 4.923
Std. Deviation 2.21880
Minimum 13.00
Maximum 20.00
Range 7.00
Interquartile Range 3.50
Skewness .493 .597
Kurtosis -.731 1.154
DR
Mean 15.4500 .70515
95% Confidence Interval for Mean
Lower Bound 13.9741 Upper Bound 16.9259
5% Trimmed Mean 15.4444
Median 15.0000
Variance 9.945
Std. Deviation 3.15353
Minimum 11.00
Maximum 20.00
Range 9.00
Interquartile Range 6.50
Skewness .332 .512
Kurtosis -1.373 .992
Tests of Normality
Kelompok Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Usia Kontrol .205 14 .115 .948 14 .528
NDR .150 14 .200* .945 14 .490
DR .117 20 .200* .977 20 .889
HbA1C
Kontrol .141 14 .200* .936 14 .369
NDR .141 14 .200* .964 14 .794
DR .106 20 .200* .984 20 .976
PVA
Kontrol .503 14 .000 .442 14 .000
NDR .534 14 .000 .297 14 .000
DR .126 20 .200* .939 20 .232
IOP
Kontrol .185 14 .200* .930 14 .301
NDR .214 14 .081 .916 14 .193
DR .207 20 .025 .883 20 .020
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Oneway
[DataSet4] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik _Rev 4.sav
Descriptives N Mean Std.
Deviation Std.
Error
95% Confidence Interval for Mean
Minimum Maximum
Lower Bound
Upper Bound
Usia
Kontrol 14 51.3571 4.90850 1.31185 48.5231 54.1912 41.00 59.00 NDR 14 51.5000 4.25622 1.13752 49.0425 53.9575 43.00 57.00 DR 20 51.9000 3.97227 .88823 50.0409 53.7591 44.00 60.00 Total 48 51.6250 4.25578 .61427 50.3892 52.8608 41.00 60.00
HbA1C
Kontrol 14 5.3857 .23812 .06364 5.2482 5.5232 5.10 5.90 NDR 14 9.5214 1.99853 .53413 8.3675 10.6753 6.20 12.70 DR 20 9.2150 1.85650 .41513 8.3461 10.0839 5.50 12.60 Total 48 8.1875 2.41481 .34855 7.4863 8.8887 5.10 12.70
ANOVA Sum of
Squares
df Mean Square F Sig.
Usia
Between Groups 2.736 2 1.368 .073 .930
Within Groups 848.514 45 18.856
Total 851.250 47
HbA1C
Between Groups 155.926 2 77.963 29.695 .000
Within Groups 118.146 45 2.625
Total 274.073 47
Nonparametric Tests
[DataSet4] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik _Rev 4.sav
Explore
[DataSet5] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik Durasi DM_Rev 4.sav
Kelompok
Case Processing Summary
Kelompok Cases
Valid Missing Total
N Percent N Percent N Percent
Durasi DM NDR 14 100.0% 0 0.0% 14 100.0%
DR 20 100.0% 0 0.0% 20 100.0%
Descriptives
Kelompok Statistic Std. Error
Durasi DM
NDR
Mean 3.5214 .85640
95% Confidence Interval for Mean
Lower Bound 1.6713 Upper Bound 5.3716
5% Trimmed Mean 3.3571
Median 3.0000
Variance 10.268
Std. Deviation 3.20437
Minimum .00
Maximum 10.00
Range 10.00
Interquartile Range 5.28
Skewness .626 .597
Kurtosis -.440 1.154
DR
Mean 9.2500 1.40464
95% Confidence Interval for Mean
Lower Bound 6.3100 Upper Bound 12.1900
5% Trimmed Mean 9.1667
Median 9.0000
Variance 39.461
Std. Deviation 6.28176
Minimum .00
Maximum 20.00
Range 20.00
Interquartile Range 11.75
Skewness .020 .512
Kurtosis -1.539 .992
Tests of Normality
Kelompok Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Durasi DM NDR .141 14 .200* .913 14 .177
DR .175 20 .109 .905 20 .052
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
T-Test
[DataSet5] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik Durasi DM_Rev 4.sav
Group Statistics
Kelompok N Mean Std. Deviation Std. Error Mean
Durasi DM NDR 14 3.5214 3.20437 .85640
DR 20 9.2500 6.28176 1.40464
Independent Samples Test Levene's
Test for Equality of
Variances
t-test for Equality of Means
F Sig. t df Sig.
(2- tailed
)
Mean Differenc
e
Std. Error Differenc
e
95% Confidence Interval of the
Difference Lower Upper
Duras i DM
Equal variance s assumed
16.46 3
.00 0
- 3.12 9
32 .004 -5.72857 1.83073 - 9.4576 4
- 1.9995 1
Equal variance s not assumed
- 3.48 2
29.74 4
.002 -5.72857 1.64513 - 9.0895 9
- 2.3675 6
Crosstabs
[DataSet2] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Karakteristik SDR _Rev 4.sav
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
SDR * Kelompok 20 100.0% 0 0.0% 20 100.0%
SDR * Kelompok Crosstabulation
Kelompok Total DR
SDR
1.00 Count 5 5
% within Kelompok 25.0% 25.0%
2.00 Count 6 6
% within Kelompok 30.0% 30.0%
3.00 Count 2 2
% within Kelompok 10.0% 10.0%
4.00 Count 7 7
% within Kelompok 35.0% 35.0%
Total Count 20 20
% within Kelompok 100.0% 100.0%
Explore
[DataSet3] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Rev 4.sav
Kelompok
Case Processing Summary
Kelompok Cases
Valid Missing Total
N Percent N Percent N Percent
CT Kontrol 25 100.0% 0 0.0% 25 100.0%
NDR+DR 50 100.0% 0 0.0% 50 100.0%
Descriptives
Kelompok Statistic Std. Error
CT Kontrol
Mean 274.8400 15.16286
95% Confidence Interval for Mean Lower Bound 243.5454 Upper Bound 306.1346
5% Trimmed Mean 274.4556
Median 273.0000
Variance 5747.807
Std. Deviation 75.81429
Minimum 148.00
Maximum 409.00
Range 261.00
Interquartile Range 98.00
Skewness .124 .464
Kurtosis -.519 .902
NDR+DR Mean 264.0200 7.70001
95% Confidence Interval for Mean Lower Bound 248.5462 Upper Bound 279.4938
5% Trimmed Mean 263.9667
Median 260.0000
Variance 2964.510
Std. Deviation 54.44731
Minimum 122.00
Maximum 429.00
Range 307.00
Interquartile Range 62.00
Skewness .078 .337
Kurtosis 1.152 .662
Tests of Normality
Kelompok Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CT Kontrol .105 25 .200* .961 25 .435
NDR+DR .091 50 .200* .981 50 .599
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
T-Test
[DataSet3] D:\PROJECT\2020\6. JUNI\Dr Joan Jurnal\SPSS Dr Joan Jurnal Rev 4.sav
Group Statistics
Kelompok N Mean Std. Deviation Std. Error Mean
CT Kontrol 25 274.8400 75.81429 15.16286
NDR+DR 50 264.0200 54.44731 7.70001
Independent Samples Test Levene's
Test for Equality of
Variances
t-test for Equality of Means
F Sig. t df Sig.
(2- tailed)
Mean Difference
Std. Error Difference
95% Confidence Interval of the
Difference Lower Upper
CT Equal variances assumed
3.291 .074 .709 73 .480 10.82000 15.25693 - 19.58702
41.22702
Equal variances not assumed
.636 36.776 .529 10.82000 17.00595 - 23.64441
45.28441
Lampiran 7
DAFTAR RIWAYAT HIDUP Nama Lengkap : Joan Sherlone T. Hutabarat Tempat/Tanggal Lahir : Pematang Siantar, 12 Juni 1989
Alamat : Tebet Timur III A No. 18, Jakarta Selatan 12820 Nama Orang Tua : dr. William E.M. Hutabarat
dr. Rumiang Tobing, SpM
Pendidikan Formal
1. SD Santo Fransiskus Asisi Jakarta (1995 – 2001) 2. SLTP Santo Fransiskus Asisi Jakarta (2001 – 2004) 3. SMA Negeri 26 Jakarta (2004 – 2005)
4. SMA PSKD 1 Jakarta (2005 – 2007)
5. Program Studi Pendidikan Dokter Umum Fakultas Kedokteran Universitas Padjadjaran Bandung (2007 – 2013)
6. Program Pendidikan Dokter Spesialis 1 Ilmu Kesehatan Mata Fakultas Kedokteran Universitas Padjadjaran / Pusat Mata Nasional Rumah Sakit Mata Cicendo Bandung (2016 – 2020)
Pengalaman Kerja
1. Dokter Internship RSUD Kabupaten Bekasi (2013 – 2014) 2. Dokter Umum Klinik Sukaseuri (2015 – 2016)